On November 1, 2023 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m. ET (Press release, Molecular Partners, NOV 1, 2023, View Source [SID1234636569]). Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Dr. Philippe Legenne, acting CMO.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "News and Events" page in the "Events" section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation date.